country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-40354S2

Copy Link Print Information

Tofacitinib-¹³C,d₃

Name: Tofacitinib-13C,d3
Brand: MedChemExpress
SKU: HY-40354S2
Availability: PreOrder

(Synonyms: Tasocitinib-¹³C,d₃; CP-690550-¹³C,d₃)

Tofacitinib-¹³C,d₃ (Tasocitinib-¹³C,d₃; CP-690550-¹³C,d₃) is the deuterated, ¹³C-labeled Tofacitinib (HY-40354). Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury.

For research use only. We do not sell to patients.

Formula: C₁₅¹³CH₁₇D₃N₆O
Molecular Weight:316.38

Storage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (286 KB)

Tofacitinib-¹³C,d₃ Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Application
Chemical Information
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]^[9]

JAK1

JAK3

STAT1

NF-κB

STAT6

STAT3

All JAK Isoforms :

All STAT Isoforms :

All NF-κB Isoforms :

Application

1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.

Chemical Information

Unlabeled CAS 477600-75-2
Molecular Weight 316.38
Formula C₁₅¹³CH₁₇D₃N₆O
SMILES

C[C@H]1[C@H](CN(CC1)C(CC#N)=O)N(C2=C3C=CNC3=NC=N2)[13C]([2H])([2H])[2H]
Synonyms

Tasocitinib-¹³C,d₃; CP-690550-¹³C,d₃
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Gao YN, et al. Tofacitinib prevents depressive-like behaviors through decreased hippocampal microgliosis and increased BDNF levels in both LPS-induced and CSDS-induced mice. Acta pharmacologica Sinica. 2025 Feb;46(2):353-365. [Content Brief]

[2]. Sendo S, et al. Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice. Arthritis research & therapy. 2019 Aug 06;21(1):184.

[3]. Zhang X, et al. Tofacitinib reduces acute lung injury and improves survival in a rat model of sepsis by inhibiting the JAK-STAT/NF-κB pathway. Journal of inflammation (London, England). 2023 Feb 03;20(1):5.

[4]. Wang W, et al. The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. Journal of scleroderma and related disorders. 2020 Feb;5(1):40-50.

[5]. Wei X, et al. Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis. Molecular pharmaceutics. 2018 Aug 06;15(8):3456-3467.

[6]. Fleischmann R, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012 Aug 9;367(6):495-507.

[7]. Sandborn WJ, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012 Aug 16;367(7):616-24.

[8]. Furumoto Y, et al. Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. Arthritis & rheumatology (Hoboken, N.J.). 2017 Jan;69(1):148-160.

[9]. Wang H, et al. The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice. Molecular medicine reports. 2019 Dec;20(6):4883-4892.

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote

Amount: USD 0.00

Biological Activity
- Description
- IC₅₀ & Target
- Application
Chemical Information
Purity & Documentation
References

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Tofacitinib-¹³C,d₃

All JAK Isoforms

All STAT Isoforms

All NF-κB Isoforms